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There is insufficient data in the literature concerning optimal intralesional kenalog (ILK) dosing for the treatment
of alopecia areata (AA). The purpose of this pilot study was to evaluate the utility of using the ratio of ILK received
to initial Severity of Alopecia Tool (SALT) score to guide ILK dosing in patients with AA. Using photographic data
from patients at baseline and 4-months follow-up, hair loss in 15 patients treated with AA was retrospectively
graded using the SALT scores. The ILK received/initial SALT score (ILK index) was calculated for each patient, and
the mean ILK index for patients who experienced significant (Z50%) and suboptimal (o50%) hair regrowth at 4
months follow-up were compared. Patients who experienced suboptimal hair regrowth had a lower ILK index on
average than patients who experienced significant improvement. Although the difference did not meet
significance (o0.1), the trend suggests that the ILK index, a novel calculation, may be a useful tool for guiding
ILK dosing in the treatment of AA.
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INTRODUCTION
Alopecia areata (AA) is an autoimmune skin disease char-
acterized by episodes of patchy to total hair loss, most
commonly on the scalp. The age of onset, extent of scalp
involvement and time to recovery for discrete episodes varies
greatly from patient to patient, which has complicated efforts
to study the efficacy of treatments designed to modify the
course of hair loss and recovery. Among the treatments
currently used to treat this condition are intralesional kenalog
(ILK) injections, which have long served as first-line therapy in
the management of AA. However, despite the widespread use
of ILK in the management of AA, research concerning the
overall efficacy, the optimal concentration and quantity of
dosing remains incomplete.
Research on the impact of ILK in AA has been
challenged by inconsistent methodology and absence of a
standard method of grading hair loss and regrowth. In 2004,
(Olsen et al., 2004) offered a solution to one of the major
challenges facing AA researchers with the creation of the
Severity of Alopecia Tool (SALT), which provides a
standardized method of quantifying hair loss and regrowth.
In 2011, (Olsen, 2011) furthermore outlines an extensive
list of factors shown to be associated with AA, which
should be collected from each patient’s past medical history
when performing studies of treatment response. Currently, a
gap in the literature pertains to optimal dosing of ILK
for treatment of AA. This retrospective pilot study was
performed to investigate the utility of the ILK index (ratio of
ILK received/initial SALT score) in predicting hair regrowth
after onset of a new episode of AA.
RESULTS
At 4 months follow-up, patients with a significant improve-
ment in their SALT score (Z50%) had a higher ILK index
(mean 8.14, SD¼5.36) than patients with suboptimal
improvement in SALT score (mean 3.96, SD¼ 3.08). Although
the difference did not meet significance, the trend (Po0.1)
suggests that a larger study is warranted to evaluate the
relationship between ILK index and ILK treatment outcomes
in patients with AA. Notably, patients with significant
improvement in hair regrowth had a shorter duration on
average of hair loss than those who experienced significant
regrowth. Although the difference did not meet significance, it
is important to note that the group with significant improve-
ment may have had a higher rate of spontaneous regrowth
than the patients with suboptimal outcomes.
FUTURE DIRECTIONS
For the next phase, the study will be expanded to include
more patients. Data from the larger sample will be analyzed to
identify the ILK index at which % improvement is maximized,
providing an opportunity to guide future recommendations for
ILK dosing in patients affected by AA. Figure 1: patient who
experienced significant improvement over 4-month treatment
period. Age: 51, female. Duration of new lesion before
treatment: 6 months. Initial SALT: 25.2%, final SALT: 2.4%.
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MATERIALS AND METHODS
Approval to conduct this clinical investigation was granted by the
Cleveland Clinic’s Internal Review Board. All patients considered for
the study signed a written consent form permitting photographs taken
during treatment to be used for research and educational purposes.
Fifteen patients met the inclusion criteria, which included: new
episode of AA (duration o2 years) with no treatment received for
the episode before the baseline photos. Baseline and 4-month follow-
up photos for each patient had to be available, and the patient needed
to be treated with a known amount and concentration of ILK during
the time between baseline and 4-month follow-up photos (Figure 1).
The patient sample was 13.3% male, 33.3% African American,
60% Caucasian, 6.7% Hispanic, average age of 51.9 years, average
duration of current alopecia episode was 29.9 weeks before pre-
sentation. Eleven patients experienced significant improvement in
their SALT score over the 4 month treatment period; four patients
experienced suboptimal improvement. (Figure 2) Factors associated
with AA outcomes, including duration of hair loss episode and
number of previous episodes of alopecia, were compared between
patients in the significant and suboptimal treatment response
groups. (Table 1) Additional factors considered were number of ILK
Baseline 4-months follow-up
Figure 1. Patient who experienced significant improvement over 4-month treatment period. Age: 51, female. Duration of new lesion before treatment: 6 months.
Initial SALT: 25.2%, final SALT: 2.4%. Photos published with patient’s permission.
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Figure 2. Number of patients in each treatment response group. .
Table 1. Table of inter-group demographic and
treatment comparisons
o50%
improvement
Z50%
improvement
P-
value
No. of autoimmune
conditions
0.75 0.73 o0.95
No. of previous AA
episodes
1.33 0.89 o0.68
Duration current AA
episode
48 (weeks) 11 (weeks) o0.33
No. of ILK admin sessions 4.25 4.36 o0.91
Frequency ILK admin 41.5 days 31.2 days o0.34
Age 58.5 years 44.8 years o0.25
Initial SALT score 11.5% 7.6% o0.32
ILK index 3.96 8.14 o0.1
Abbreviations: AA, alopecia areata; ILK, intralesional kenalog; SALT,
Severity of Alopecia Tool.
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Figure 3. Inter-group comparison of the average number of ILK
administration sessions received over the 4-month treatment period. .
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administration sessions (Figure 3) and frequency of ILK administra-
tion. (Figure 4) There were no significant differences between the two
groups in these areas.
SALT scores were generated by consensus of four board-certified
Dermatologists through grading of photos from baseline and 4-month
follow-up. The ILK index was calculated by totaling the milligrams of
ILK received over the treatment period (ILK concentration multiplied
by the number of milliliters injected, totaled over the 4-month
treatment period), divided by the patient’s baseline SALT score.
‘‘Significant improvement’’ in SALT score was defined as Z50%
improvement; suboptimal improvement in SALT score was defined as
o50% improvement. The mean ILK index for each group was
compared using Welch’s test, with a P-value of 0.05 to meet
significance (Figure 5).
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Figure 4. Inter-group comparison of the average number of days between ILK
administration sessions. .
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Figure 5. Inter-group comparison of the ILK index. .
AM Stallings et al.
ILK Index and Regrowth in Alopecia Areata
www.jidonline.org 49
